vascuCAP
Overview
Elucid Bioimaging (also known as Elucid Bio) is a Boston-based medical technology company that leverages artificial intelligence to provide physicians with advanced tools for diagnosing and treating cardiovascular disease. Its flagship product, originally known as vascuCAP and now often referred to as ElucidVivo or PlaqueIQ, is an FDA-cleared software designed for the non-invasive analysis of CT angiograms (CTA).
The software objectively quantifies and characterizes atherosclerotic plaque, including components like lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage, using algorithms validated against ground-truth histology. It provides multi-dimensional visualization and detailed reports of arterial vessels and plaque composition, aiding clinicians in risk stratification for major cardiovascular events such as stroke and heart attack. Elucid’s technology aims to optimize treatment decisions, leading to improved patient outcomes and reduced healthcare costs by offering a more precise, patient-specific view of atherosclerosis.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-enabled CT angiogram analysis
- Histologically-validated plaque quantification and characterization
- 3D visualization of arterial vessels and plaque
- Risk stratification for stroke and heart attack
- Support for personalized treatment decisions
- Quantification of lipid-rich necrotic core, calcification, non-calcified matrix, intraplaque hemorrhage
- DICOM integration and PACS/EMR interoperability
- Cloud and on-premise secure deployment options
- Fractional Flow Reserve CT (FFRct) estimation (research/upcoming)
- Clinician-facing reports and graphical results
Use Cases
- Atherosclerotic plaque assessment and quantification
- Stroke risk prediction and prevention
- Heart attack risk prediction and prevention
- Optimizing personalized treatment for cardiovascular disease
- Clinical trials and research studies in vascular health
- Evaluating plaque vulnerability from CTA
What Physicians Need to Know
vascuCAP provides physicians with objective, histologically-validated quantification and 3D visualization of atherosclerotic plaque from CTAs and MRIs, enabling more informed and precise treatment decisions for patients with known or suspected cardiovascular disease. It can help identify patients at higher risk of stroke or heart attack by characterizing plaque composition and stability beyond traditional stenosis assessments, potentially guiding interventions or intensive therapeutics. The ability to non-invasively estimate FFR can also aid in determining the need for surgical intervention, potentially reducing the reliance on invasive procedures.
vascuCAP has been integrated into the IBM Imaging AI Marketplace, an IBM Watson Health solution. This integration provides streamlined access to this AI technology for professionals in radiology and cardiology, facilitating its deployment and management within existing healthcare IT infrastructures.
Details
| Category | Cardiology AI, Clinical Decision Support & Reference |
| Pricing | Contact for pricing |
| Deployment | Cloud and on-premise |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated Elucid's vascuCAP (K183012, cleared 12/21/2018), ElucidVivo (K221463, cleared 06/17/2022), and PlaqueIQ (K241524, cleared 10/01/2024) are FDA-cleared Class II medical image analysis systems. They are intended to assist trained physicians in the non-invasive evaluation and assessment of plaque quantification and morphology from previously acquired CT angiography images for patients identified with atherosclerosis. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Radiology, Vascular Surgery |
What the Web Says
Elucid's vascuCAP, now known as ElucidVivo, is an AI-powered software designed to analyze CT angiograms (CTA) to characterize and quantify atherosclerotic plaque. Studies suggest it significantly improves the accuracy of stroke prediction compared to traditional stenosis-based methods. The technology is in clinical use and has received FDA clearance and a CE mark.
Overall: PositiveStrengths
- Improved accuracy in stroke prediction (up to 70% more accurate than stenosis-based methods).
- Objectively quantifies key drivers of stroke and heart attack from CTA.
- Provides detailed 3D visualization and quantification of plaque tissue composition.
- Validated by histology for accurate tissue classification.
- Can identify endothelial damage, a COVID-19 complication linked to stroke.
- Offers on-site analysis in minutes, aiding informed clinical decision-making.
Limitations
- No specific cons were found in the provided search results regarding vascuCAP/ElucidVivo.
- General Reddit discussions about other vascular-related medications or companies (Vascepa, VascuTech Medical LLC) show mixed reviews for those distinct entities, but these are not directly related to Elucid's vascuCAP software.
Based on reviews from: MD+DI, AuntMinnie, BioWorld MedTech, Business Wire, BioSpace
Last updated: 2026-07-18
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate vascuCAP
Frequently Asked Questions
Compare vascuCAP
VS
VS
VS
VS
